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Abstract
Background: Epithelial cell adhesion molecule (EpCAM) has been used as surrogate marker for the quantification
of circulating tumour cells (CTC). Our aim was to prospectively study the value of a real-time RT-PCR assay for
EpCAM detection in the peripheral blood and peritoneal cavity of patients undergoing pancreatectomy for
pancreatic ductal adenocarcinoma (PDAC).
Methods: From 48 patients with PDAC (40 resectable, 8 unresectable) and 10 patients with chronic pancreatitis
undergoing pancreatectomy 10 ml of venous blood was drawn preoperatively (PB) and postoperatively (POB, day 1
(D1B), day 7 (D7B) and after 6 weeks (6WB). Of all patients undergoing pancreatectomy, 40 ml peritoneal lavage
fluid was taken preoperatively and postoperatively. A real-time RT-PCR assay (TaqMan, ABI Prism 7700) was
developed for the detection of EpCAM mRNA. To discriminate between EpCAM-positive and negative samples a
cut-off was applied. Median postoperative follow-up was 24.0 months (range: 0.7 - 41.3).
Results: PB was EpCAM-positive (+) in 25% of patients versus 65% of patients in POB (p < 0.0001). EpCAM(+) was
noted at D1B, D7B and 6WB was found in 28.6%, 23.1% and 23.5% of patients respectively. Preoperative peritoneal
lavage fluid was EpCAM(+) in 10.3% versus 53.8% of patients postoperatively (p < 0.0001).
At none of the time-points, an association was found between EpCAM positivity in blood and/or peritoneal cavity
and cancer-specific or disease-free survival. Also, no significant associations were found between clinicopathological
variables and perioperative EpCAM positivity.
Conclusions: Despite a significant increase in EpCAM counts in postoperative blood and peritoneal lavage fluid
this was not associated with worse prognosis after pancreatectomy for PDAC.
Trial registration: Clinicaltrials.gov NCT00495924
Background
The vast majority of patients suffering from solid organ
tumours, such as pancreatic cancer, ultimately die from
metastases that develop at sites far from the primary
tumour. These distant organ metastases are the end-
results of a mainly haematogenous cancer cell dissemi-
nation from the primary tumour. Pancreatic cancer or
pancreatic ductal adenocarcinoma (PDAC) is one of the
most lethal malignancies in humans. In selected patients
with localised PDAC, surgical resection is the only treat-
ment offering long-time survival. Despite the curative
intent of surgical resection, cancer recurrence in the
liver and/or the peritoneal cavity develops within two
years after pancreatic surgery in over 60% of patients
[1]. Therefore, recent evidence supports that surgical
resection of solid tumours could promote tumour
escape [2,3]. Indeed, intraoperative tumour manipulation
results in detachment of tumour cells that may cause
metastases [4]. Additionally, the postoperative phase is
characterized by transient changes in the immune
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dering the host more susceptible to metastasis. The
release of certain mediators (e.g. IL-6, IL-8, VEGF) in
the acute phase response and tissue healing has been
shown to have a stimulatory effect on the growth of
minimal residual disease. Altogether, despite that com-
plete surgical resection offers the only chance for long-
term survival in many solid organ cancers, surgery may
come at a cost due to major changes in the periopera-
tive period. Therefore, the perioperative period, which is
at present almost unexploited, may also represent a win-
dow for novel therapeutic opportunities. Bearing this in
mind, further characterization and quantification of cir-
culating tumour cells (CTC) in the perioperative phase
might help us find new therapeutic targets and predic-
tive markers specific for the haematogenous metastatic
route [5]. Despite the fact that specific isolation of CTC
is a difficult pursuit, quantification of CTC has been
found to possess significant prognostic value in numer-
ous solid epithelial tumours [6-8]. Tumour cells have
been detected and quantified in whole blood using the
immunomagnetic EpCAM-based CellSearch
® system
(Johnson & Johnson). The epithelial cell adhesion mole-
cule (EpCAM) protein is commonly expressed on nor-
mal epithelial and overexpressed on malignant cells in a
subset of human carcinomas [9]. For some authors the
sensitivity of the CellSearch
® system, a slide-based cell
counting technique has been a subject of concern. This
likely reflects the fragility of CTC [10]. In contrast,
molecular quantitative detection assays such as real-time
qRT-PCR have much higher sensitivity. Real-time qRT-
PCR has never been explored to detect EPCAM mRNA
in patients with PDAC.
The primary aim of the current study was to prospec-
t i v e l ys t u d yt h ev a l u eo far e a l - t i m eR T - P C Ra s s a yf o r
EpCAM detection in the peripheral blood and peritoneal
cavity of patients undergoing pancreatectomy for PDAC.
Our secondary aim was to study correlations between
CTC detection and clinical or pathological variables.
Methods
Patients
Between September 2004 and July 2006 we prospectively
included 40 patients undergoing pancreatic resection
(PR) for PDAC, 8 patients with unresectable PDAC, 10
patients with chronic pancreatitis and 3 healthy volun-
teers. Pathological diagnosis was confirmed by micro-
scopic evaluation of the resected specimen or tumour
biopsy for unresectable cancers. Patients with pancreatic
cancer were classified according to the 7
th edition of the
AJCC TNM cancer staging system [11]. Of all resectable
PDAC, 2 (5%) had stage Ib, 11 (27.5%) had stage IIa, 26
(65%) had stage IIb and one patient had stage IV
disease.
Approval was obtained from the local ethical commit-
tee prior to the start of patient recruitment. Written
informed consent was obtained from all included
patients.
Surgery
Two experienced hepatobiliary surgeons (RA and BT)
performed all surgical procedures. A right para-aortic
lymph node dissection was carried out routinely for sta-
ging purpose in pancreatic head tumours and followed
by pancreaticoduodenectomy in case no metastatic
lymph nodes were found at frozen section pathology. In
the case of metastatic para-aortic lymph nodes a pan-
creaticoduodenectomy was not performed. The surgical
resection margins of the common hepatic duct and the
pancreatic transection surface were systematically exam-
ined on intra-operative frozen sections.
Samples
EDTA-treated venous blood samples (10 ml) were
obtained in patients undergoing PR before surgery (PB,
n = 40, see Table 1), immediately after surgery at skin
closure (POB, n = 40), at postoperative day 1 (D1B, n =
35), day 7 (D7B, n = 39) and after 6 weeks (6WB, n =
34). Blood samples were taken via a central venous line
(except in healthy volunteers) in order to avoid contami-
nation with skin epithelial cells. Peripheral blood mono-
nuclear cells (PBMC) were isolated after erythrocyte
lysis with 10 ml ammonium-chloride lysis buffer, resus-
pended, pooled and washed in Ca
2+/Mg
2+ -free phos-
phate buffered saline. Next, cells were lysed and
homogenized in RLT buffer (Qiagen) following the man-
ufacturers instructions.
Peritoneal lavage was performed in patients under-
going PR prior to exploration of the abdominal cavity
(PP) and prior to laparotomy closure (POP). A volume
of 500 ml of sterile isotonic sodium chloride solution
was instilled and 40 ml was removed after irrigation.
These samples were centrifuged at 1500 rpm for
10 minutes at 4°C in a swing-bucket centrifuge. The
supernatant was removed and the sediment was diluted
and washed with 10 ml of erythrocyte lysis buffer. Next,
cells were counted, lysed and homogenized in RLT buf-
fer (Qiagen). All cell lysates were stored at -80°C until
total RNA was extracted.
Tumour (T) and surrounding non-tumoural control
samples (P) were immediately stored in RNAlater
® (Qia-
gen) and transferred for storage to -80°C according to
the manufacturers’ instructions. Haematoxylin and eosin
stains were made from each tumour sample to verify
that the sample contained more than 70% tumour and
from control pancreatic tissue to confirm its non-
cancerous histology. In 16/40 patients RNA was
extracted from the T and P samples.
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Total RNA from blood and peritoneal lavage fluid was
extracted using the RNeasy kit (Qiagen). Total RNA was
isolated from tissue sections using a protocol combining
Trizol/chloroform extraction, followed by column chro-
matography with the RNeasy Mini kit (Qiagen).
RNA integrity was quantified spectrophotometrically
(Genequant). Copy DNA was synthesised from 4 μgo f
total RNA.
Real-time RT-PCR assay
EpCAM and control gene Beta-glucuronidase (GUS) pri-
mers and probes were designed to span exon-intron
boundaries. Amplification, detection and quantification
were performed with the TaqMan™ ABI Prism 7700
sequence detection system (Applied Biosystems) and
have been previously described [12]. Copy DNA was
diluted to obtain a starting amount of 100 ng mRNA.
Each sample was analyzed in duplicate. Copy numbers
of the target template were quantified in peripheral
blood and peritoneal fluid through generation of stan-
dard curves by serial dilution of plasmids for EpCAM
and the housekeeping gene b-glucuronidase (GUS)
(10
5 -1 0
1 plasmid copies). All measured copies for
EpCAM were normalized (i.e. normalized copy number
(NCN)) to the quantities obtained for GUS.
Cut-off strategy
Due to the background transcription in the blood and
peritoneal lavage samples of the control group a cut-off
was determined to differentiate between EpCAM posi-
tivity and negativity. The samples that exceeded the
upper limit of the 95% confidence interval of NCN of
EpCAM in the control group were defined as EpCAM
mRNA positive.
Follow-up
Follow-up data were recorded from the patient’s medical
records and completed by a telephone survey performed
on the 1
st of April 2010, contacting the patient’s general
practitioner and/or oncologist. Postoperative mortality
was defined as in-hospital mortality as from any post-
operative complication. Cancer-specific survival (CSS)
was defined as the time period from the date of surgery
until any death after prior exclusion of postoperative
deaths. Disease-free survival (DFS) was defined as the
time interval between surgical resection and first recur-
rence of disease. First recurrence was classified as recur-
rence in loco, distant recurrence, or a combination of
both. Median postoperative follow-up was 24.0 months
(range: 0.7 - 41.3).
Statistics
Statistical calculations were carried out using JMP ver-
sion 8.0.1 for Mac (SAS).
The Student t test was performed to compare contin-
uous data. The Fisher’s exact test was used to compare
categorical data whenever appropriate. The McNemar’s
test was used to compare paired proportions. The asso-
ciations between EpCAM positivity was examined for
the following clinical and histological parameters: age
Table 1 Clinical and pathological characteristics of
included patients
EpCAM (+)
N=1 0
EpCAM (-)
N=3 0
Total
N=4 0
p-value
Age (±SD) 56.3 (±10.0) 65.7 (±9.5) 63.3 (±10.3) 0.01
Gender (M:F) 5:5 18:12 23:17 NS
pG NS
1 0 3 (10.0%) 3 (7.5%)
2 2 (20%) 12 (40.0%) 14 (35.0%)
3 8 (80%) 15 (50.0%) 23 (57.5%)
pT NS
1 0 2 (6.7%) 2 (5.0%)
2 0 4 (13.3%) 4 (10.0%)
3 10 (100%) 24 (80.0%) 34 (85.0%)
pN NS
0 3 (30.0%) 10 (33.0%) 13 (32.5%)
1 7 (70.0%) 20 (67.0%) 27 (67.5%)
AJCC stage NS
Stage IA 0 2 (6.7%) 2 (5.0%)
Stage IB 3 (30.0%) 8 (26.7%) 11 (27.5%)
Stage IIA 0 1 (3.3%) 1 (2.5%)
Stage IIB 7 (70.0%) 18 (60.0%) 25 (62.5%)
Stage III 00 0
Stage IV 0 1 (3.3%) 1 (2.5%)
ECLNI NS
0 7 (70.0%) 27 (90.0%) 34 (85%)
1 3 (30.0%) 3 (10.0%) 6 (15%)
Total LN count 16.5 (10 - 39) 17 (6 - 35) 17 (6 - 39) NS
LVI * NS
0 3 (33.3%) 20 (69.0%) 12 (31.6%)
1 6 (66.7%) 9 (31.0%) 26 (68.4%)
PNI NS
0 1 (10.0%) 7 (23.3%) 8 (15%)
1 9 (90.0%) 23 (76.7%) 32 (85%)
NS: non-significant; pG: tumour differentiation grade; pN: lymph node status;
ECLNI: Extracapsular lymph node involvement; LVI: lymphovascular invasion;
PNI: perineural invasion.
* In 2 patients the presence of LVI was not evaluated.
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lymph node metastasis (pN), tumour depth (pT), resec-
tion margin positivity (R), perineural invasion (PNI),
lymphovascular invasion (LVI), extracapsular lymph
node involvement (ECLNI) and total lymph node
counts. Survival rates for CSS and DFS were estimated
according to the Kaplan-Meier method using Log-Rank
statistics for comparison. Two-sided P-values ≤ 0.05
were considered statistically significant.
Results
Primary tumour versus surrounding non-tumoural
pancreatic tissue
Median (range) NCN (×1000) for EpCAM was 11800.1
(4357.7 - 39142.8) versus 7552.5 (475.2 - 13765.5) in
tumour and non-tumoural surrounding pancreatic tissue
respectively (p = 0.014). No significant correlations were
found between pT, pG, pN, ECLNI, LVI, R and EpCAM
expression in tumour or non-tumoural surrounding tis-
sue. EpCAM expression was significantly increased in
tumours with perineural invasion (p = 0.050).
Perioperative detection of EpCAM in blood
NCN were significantly higher in preoperative blood
(PB) of unresectable PDAC versus resectable PDAC,
with a median (range) of 149.3 (77.8 - 2855.6) NCN
(×10
4) versus 122.3 (9.5 - 2307.1) respectively (p =
0.014). EpCAM detection in blood increased signifi-
cantly immediately after resection of PDAC with a
median (range) of 397.7 (6.67 - 6891.9) NCN (×10
4)( p
= 0.001) (Figure 1). In contrast, no significant differ-
ence was found in NCN of PB between resectable
PDAC and non-tumoural controls (benign pancreatic
disease and HV) with a median (range) of 122.3 (9.5 -
2307.1) NCN (×10
4) versus 157.1 (16.5 - 483.4) respec-
tively (p = 0.60).
The upper limit of the 95% confidence interval of
NCN (×10
4) in preoperative blood of the control sam-
ples was 285.4. After dichotomization, preoperative
blood was EpCAM(+) in 10/40 (25%) patients compared
to 27/40 (67.5%) patients immediately after pancreatic
resection (p < 0.0001).
For D1B, D7B and after 6 weeks, EpCAM positivity in
blood was seen in 10/35 (28.6%), 9/39 (23.1%) and 8/34
(23.5%) patients undergoing PR respectively. In unre-
sectable PDAC blood was EpCAM (+) in 2/8 (25%)
patients.
No significant associations were found for preopera-
tive (Figure 2 and 3) and postoperative (PoB, D1B, D7B
a n d6 W B )E p C A Mp o s i t i v i t yi nb l o o da n dC S So rD F S .
Also, no significant associations were found for preo-
perative EpCAM positivity and pG, pT, pN, PNI, LVI,
ECLNI and total lymph node counts. (Table 1) Finally,
EpCAM expression in the primary tumour did not
correlate with EpCAM positivity in preoperative blood
(data not shown).
Peritoneal detection of EpCAM
No significant difference was observed in EpCAM NCN
in preoperative peritoneal lavage fluid between resect-
able (N = 39) and unresectable (N = 8) PDAC despite a
median (range) NCN (×10
3) of 161.5 (3.39 - 31855.4)
and 1539.6 (23.5 - 15059.3) respectively (p = 0.49). Simi-
larly, no significant difference was found in EpCAM
counts in preoperative peritoneal lavage specimens
between resectable PDAC and non-tumoural controls
(benign pancreatic disease). On the other hand, a signifi-
cant difference in NCN was found between preoperative
and postoperative peritoneal lavage specimens (p =
0.001) (Figure 4).
The upper limit of the 95% confidence interval of
NCN (×10
3) in preoperative peritoneal lavage specimens
of the control samples was 1636.8. After dichotomiza-
tion, preoperative lavage fluid was EpCAM(+) in 4/39
(10.3%) patients who underwent pancreatic resection
compared to 21/39 (53.8%) patients immediately after
pancreatic resection (p < 0.0001).
No significant associations were found for preopera-
tive and postoperative (PoB, D1B, D7B and 6WB)
EpCAM positivity in peritoneal lavage fluid and CSS or
DFS (data not shown). Similar to EpCAM positivity in
preoperative blood, no significant associations were
found for preoperative EpCAM positivity in peritoneal
l a v a g ef l u i da n dp G ,p T ,p N ,P N I ,L V I ,R ,E C L N Ia n d
total lymph node counts. Finally, EpCAM expression in
the primary tumour did not correlate with EpCAM
positivity in the preoperative peritoneal lavage fluid
(data not shown).
Discussion
The current study is the first using an EpCAM-based
real-time RT-PCR assay to detect, quantify and evaluate
the prognostic effect of circulating tumour cells in per-
ipheral blood and peritoneal lavage fluid in any gastroin-
testinal cancer. Only one other research group studied
the diagnostic potential of quantitative RT-PCR by
detecting disseminated tumour cells based on cytokera-
tin-19 mRNA in blood, bone marrow and peritoneal
lavage in patients with ductal adenocarcinoma of the
pancreas [13].
Our study shows that peri-operative detection of
EpCAM is not associated with worse oncological out-
come. Nevertheless, significantly higher NCN were
found in preoperative blood for unresectable versus
resectable PDAC (p = 0.014). EpCAM detection was
higher immediately after surgical resection (PoB), to
decrease almost to preoperative levels as of postopera-
tive day 1. Despite a significant increase in EpCAM
Sergeant et al. BMC Cancer 2011, 11:47
http://www.biomedcentral.com/1471-2407/11/47
Page 4 of 8Figure 1 Haematogenous cancer cell dissemination in patients undergoing pancreatic resection for PDAC. Quantification of EpCAM
transcripts in blood using real-time RT-PCR. The postoperative amounts are only significantly higher for PoB versus PB (p < 0.0001). PB:
preoperative, PoB: postoperative; D1B: day after surgery; D7B: 7th day following surgery, 6WB: 6 weeks after surgery.
Figure 2 Cancer-specifc survival rates by EpCAM-positivity.
EpCAM (+) (N = 10, blue) and EpCAM (-) (N = 28, red) patients in
preoperative blood (PB) following pancreatic resection for PDAC
after exclusion of postoperative mortality (p = 0.17, Log-Rank).
Figure 3 Time-to-recurrence rates by EpCAM-positivity.E p C A M
(+) (N = 10, blue) and EpCAM (-) (N = 28, red) patients in
preoperative blood (PB) following pancreatic resection for PDAC
after exclusion of postoperative mortality (p = 0.28, Log-Rank).
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and peritoneal lavage fluid, no adverse effect on DFS or
CSS could be demonstrated.
Several explanations can be proposed to elucidate
these findings.
First, preoperative CTC could rather reflect intermit-
tent shedding of tumour cells than true metastatic poten-
tial of the primary tumour. Moreover, it is well
recognized that this shedding already commences at the
early stages of tumour growth. Metastasis is an inefficient
process where circulating malignant cells are eliminated
almost immediately from the blood. A very large propor-
tion - maybe the far majority - of exfoliated pancreatic
tumour cells enter the peripheral circulation via the por-
tal circulation and do not survive past the liver (i.e. first-
pass effect). Accordingly, in our study the highest CTC
load in peripheral blood was noted immediately after sur-
gery, to quickly decrease by the first postoperative day.
Thereafter the proportion of EpCAM-positive patients
remained similar to the preoperative state. These findings
a r ei nl i n ew i t hp r e v i o u s l yp u b l i s h e dr e s u l t st h a te x f o -
liated tumour cells are almost completely cleared from
the blood within 24 hours [14]. Moreover, the majority of
cells that survive, arrest and extravasate in lymph nodes,
lungs, liver and bone marrow will remain dormant for
many years and may never cause relapse of cancer.
Second, it is well known that over 80% of patients
suffering from PDAC present with unresectable disease
due to the presence of metastases or local extension.
However, to what extent the patients with potentially
resectable PDAC have distant micrometastasis at pre-
sentation is unknown. As these distant sites also contri-
bute to the pool of CTC, quantification of cancer cell
dissemination might not be such a good surrogate of
metastatic potential of the primary tumour but rather of
total tumour load.
Figure 4 Peritoneal cancer cell dissemination in patients undergoing pancreatic resection for PDAC. Quantification of EpCAM transcripts
in peritoneal lavage fluid using real-time RT-PCR. The postoperative amounts are significantly higher (p = 0.0001). PP: preoperative, PoP:
postoperative.
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tumour cell heterogeneity [15]. Indeed, not all tumour
cells have equal phenotypes. The capacity of a tumour
to grow and propagate could be dependent on a subset
of cells with the capacity of self-renewal and differentia-
tion, often termed “cancer stem cells” or “cancer-initiating
cells” [16]. According to this cancer stem cell theory only
a proportion of cancer cells, i.e. cancer stem cells are
able to proliferate extensively and form new tumours.
Both the concept of tumour cell heterogeneity and the
cancer stem cell hypothesis put a caveat on the percep-
tion of metastasis as a pure stochastic phenomenon. In
the future, quantification with high specificity of the
‘driving’ cancer cell population in the peripheral blood or
peritoneal cavity of pancreatic cancer patients, may prove
to have far better prognostic value than quantifying all
circulating cancer cells [6].
A fourth explanation is that all EpCAM-based detec-
tion systems could be associated with downregulation of
epithelial markers - and consequently also EpCAM - in
circulating tumour cells in the course of epithelial-
mesenchymal transition (EMT) [17]. Despite a significant
overexpression of EpCAM in primary PDAC compared
to surrounding non-tumoural pancreatic tissue [9],
EpCAM could still be downregulated in CTC. Neverthe-
less, the EpCAM-based semi-automated CellSearch
®
(Johnson & Johnson) system has been found to bear sig-
nificant prognostic potential. In patients with metastatic
breast [7] and colorectal cancer [18], CTC levels were
strong predictors for both progression-free survival and
overall survival and complemented the results of conven-
tional medical imaging. One must ascertain that in con-
trast with our single marker real-time RT-PCR assay, the
CellSearch
® system also checks potential tumour cells for
cytokeratin positivity, CD45 negativity and nuclear stain-
ing with DAPI and consequently should be considered a
multimarker assay. Therefore, it is probably safer to state
that any single-marker assay and a fortiori any non-can-
cer specific single-marker real-time RT-PCR study has
limited biomarker potential.
A fifth explanation could be the high background
expression of EpCAM mRNA in both chronic pancrea-
titis and healthy volunteers. Indeed, immunohisto-
chemical studies have shown increased EpCAM in
chronic pancreatitis. It is very likely that after and
even before surgical resection for chronic pancreatitis,
many different cell types including pancreatic epithelial
cell types enter the blood circulation or peritoneal cav-
ity and result in EpCAM detection. In this regard, cir-
culating epithelial cells have been detected in the
blood samples of patients undergoing colonic resection
for benign conditions [19]. Yet, another explanation
m a yb ei l l e g i t i m a t et r a n s c r iption of EpCAM in haema-
topoietic cells, i.e. a low amount of tissue specific gene
transcription is present in non-specific tissues as the
result of minimal activation of promoters by ubiqui-
tous transcription factors [20]. This phenomenon is
more often encountered when RNA is isolated from
the total white blood cell fraction (and not first
exclude granulocytes) to detect CTC.
In our study EpCAM expression in primary PDAC
samples was significantly higher in the presence of peri-
neural invasion. Nevertheless, higher EpCAM expression
was not associated with worse oncological outcome,
despite that perineural invasion is a well-established
prognostic factor in PDAC [21].
We are aware of a few shortcomings in the present
study. The total sample size is relatively small with only
48 patients with PDAC included. This small sample size
may result in both type I (false positive, e.g. the differ-
ence in EpCAM mRNA expression in unresectable ver-
sus resectable patients) and type II (false negative)
errors. The detection of disseminated tumour cells with
real-time RT-PCR depends on a number of steps includ-
ing collection and treatment of the sample, cell separa-
tion protocol, chosen antibodies, and the number of
analyzed cells. Ideally, the target gene is expressed only
by tumour cells and not by surrounding cells in the
examined compartment (i.e. the blood and peritoneal
cavity in our study). However, a high background
expression of EpCAM mRNA was also found in both
chronic pancreatitis and healthy volunteers, necessitating
application of a cut-off to discriminate between
EpCAM-positivity and negativity. Similarly in colorectal
cancer, the use of CK19, CK20 and other cytokeratins as
a marker in the assessment of CTC in peripheral blood
has been questioned primarily on the basis of high back-
ground expression in healthy volunteers [22]. Also, the
ideal enrichment strategy (e.g. red blood cell lysis, den-
sity centrifugation, magnetic bead separation) and RNA
extraction technique is still under debate, as undoubt-
edly both influence background expression. In several
peritoneal lavage samples and some blood samples, the
total starting amount of extracted RNA was less than
4 μg. After cDNA synthesis, the mixture was further
diluted to obtain a concentration of 100 ng RNA per
reaction for all samples. Nevertheless, different total
starting amounts of RNA may result in varying sensitiv-
ity of the real-time RT-PCR assay for the detection of
EpCAM in these samples. It is unclear to what extent
our results have been influenced by this. However, since
background expression in control samples was high, we
believe that the assay is more likely to lack specificity
than sensitivity.
Conclusions
Circulating tumour cell load measured by real-time RT-
PCR for EpCAM was increased significantly in the
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cancer cell dissemination does not seem to be associated
with worse prognosis in PDAC and should not be seen
as a purely stochastic phenomenon. We believe that
further study is necessary to clarify the complex interac-
tions between disseminating tumour cells, the immune
system, the acute phase response and healing process
during the perioperative period.
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